Amivantamab for previously treated, locally advanced or metastatic EGFR exon 19 deletion or exon 21 L858R substitution mutation-positive non-small-cell lung cancer

Agency for Care Effectiveness (ACE)
Record ID 32018015213
English
Details
Project Status: Completed
Year Published: 2026
URL for published report: https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidances/drug-guidance/amivantamab-for-previously-treated--locally-advanced-or-metastatic-egfr-exon-19-deletion-or-exon-21-l858r-substitution-mutation-positive-non-small-cell-lung-cancer/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Singapore
MeSH Terms
  • Lung Neoplasms
  • Carcinoma, Non-Small-Cell Lung
  • Antineoplastic Agents, Immunological
  • Antibodies, Bispecific
Contact
Organisation Name: Agency for Care Effectiveness (ACE)
Contact Address: Ministry of Health, College of Medicine Building, 16 College Road, Singapore 169854
Contact Name: ACE_HTA@moh.gov.sg
Contact Email: ACE_HTA@moh.gov.sg
Copyright: Agency for Care Effectiveness (ACE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.